Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with sign...

Early report Major update Updated Mar 18, 2026, 10:05 AM UTC

Track this event Edit in app More event pages

What changed

New report from GlobeNewswire Earnings Releases and Operating Results 1h ago.

First seen Mar 18, 2026, 10:05 AM UTC Latest source Mar 18, 2026, 10:05 AM UTC

Update 1 1h ago

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire Earnings Releases and Operating Results •published Mar 18, 2026, 10:05 AM UTC •fetched Mar 18, 2026, 10:21 AM UTC

Event stats

Reports 1

Sources 1

Confidence low

Score 41

Entity focus

OvidTherapeuticsAnnouncesNewData

Source spread

GlobeNewswire Earnings Releases and Operating Results

Turn this into an alert

Draft the watch from the event wording, then let PushMe handle follow-up changes.

Notify me about major new developments on Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results, especially in…

Create alert from this event